Pathogens and Immunity最新文献

{"title":"Pre-cART Immune Parameters in People Living With HIV Might Help Predict CD8+ T-Cell Characteristics, Inflammation Levels, and Reservoir Composition After Effective cART.","authors":"Jimena Salido,&nbsp;Alejandro Czernikier,&nbsp;César Trifone,&nbsp;María Laura Polo,&nbsp;María Inés Figueroa,&nbsp;Alejandra Urioste,&nbsp;Pedro Cahn,&nbsp;Omar Sued,&nbsp;Horacio Salomon,&nbsp;Natalia Laufer,&nbsp;Yanina Ghiglione,&nbsp;Gabriela Turk","doi":"10.20411/pai.v6i2.447","DOIUrl":"https://doi.org/10.20411/pai.v6i2.447","url":null,"abstract":"<p><strong>Background: </strong>Combined antiretroviral treatment (cART) for HIV infection is highly effective in controlling viral replication. However, it cannot achieve a sterilizing cure. Several strategies have been proposed to achieve a functional cure, some of them based on immune-mediated clearing of persistently infected cells. Here, we aimed at identifying factors related to CD8TC and CD4TC quality before cART initiation that associate with the persistence of CD8TC antiviral response after cART, inflammation levels, and the size of the viral reservoir.</p><p><strong>Methods: </strong>Samples from 25 persons living with HIV were obtained before and after (15 months) cART initiation. Phenotype and functionality of bulk and HIV-specific T cells were assayed by flow cytometry <i>ex vivo</i> or after expansion in pre-cART or post-cART samples, respectively. Cell-Associated (CA) HIV DNA (total and integrated) and RNA (unspliced [US] and multiple spliced [MS]) were quantitated by real-time PCR on post-cART samples. Post-cART plasma levels of CXCL10 (IP-10), soluble CD14 (sCD14) and soluble CD163 (sCD163) were measured by ELISA.</p><p><strong>Results: </strong>Pre-cART phenotype of CD8TCs and magnitude and phenotype of HIV-specific response correlated with the phenotype and functionality of CD8TCs post-cART. Moreover, the phenotype of the CD8TCs pre-cART correlated with markers of HIV persistence and inflammation post-cART. Finally, exhaustion and differentiation of CD4TCs pre-cART were associated with the composition of the HIV reservoir post-cART and the level of inflammation.</p><p><strong>Conclusions: </strong>Overall, this work provides data to help understand and identify parameters that could be used as markers in the development of immune-based functional HIV cure strategies.</p>","PeriodicalId":36419,"journal":{"name":"Pathogens and Immunity","volume":" ","pages":"60-89"},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714178/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39665340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An interview with Nobel Laureate David Baltimore, PhD.","authors":"Michael M Lederman,&nbsp;Neil S Greenspan","doi":"10.20411/pai.v6i2.476","DOIUrl":"https://doi.org/10.20411/pai.v6i2.476","url":null,"abstract":"In an online interview, Nobel Laureate David Baltimore, Ph.D., reflected on his contributions to biomedical science that have had a major influence on the fields of molecular biology, virology, cancer, and immunology. Dr. Baltimore is President Emeritus and Distinguished Professor of Biology at the California Institute of Technology. Among other notable works, he discovered the critical nuclear transcription factor NF Kappa B and the Rag1 and Rag2 proteins that rearrange adaptive immune cell receptors. \u0000His career path, he says, evolved naturally, as math and science came easily to him. As a high school student, he participated in a summer program at the Jackson Lab in Bar Harbor, Maine, where he says he came away feeling that experimental biology was exciting and rewarding. \u0000“That's where I discovered that the frontiers of science, were not so distant; that I could actually make a discovery that nobody else in the world knew about,” he says.  \u0000And that he did. Independently, he and Howard Temin discovered the viral enzyme reverse transcriptase revising the canon of cellular information transfer. They published back-to-back papers in Nature demonstrating that this enzyme in virus particles could transcribe RNA to DNA. Both received a Nobel Prize for this work. \u0000In reflecting on his early experience evaluating how to work with recombinant DNA and how we should scientifically and safely approach gain of function research, he says, “We have to be very honest with ourselves about what might hold danger, and we have to control our instinct … to do anything we can to generate progress and understanding of life. …At the same time, we don’t want to hold back progress, and so there is a balancing.” \u0000Dr. Baltimore also discussed his optimism about vectored immunoprophylaxis as a strategy for prevention of HIV and his doubt that scalable strategies will be able to cure HIV. He also reflected on his philosophy for the training of young scientists and the successful training program that he developed at the Whitehead Institute.","PeriodicalId":36419,"journal":{"name":"Pathogens and Immunity","volume":" ","pages":"50-59"},"PeriodicalIF":0.0,"publicationDate":"2021-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39483600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Generation of a Novel SARS-CoV-2 Sub-genomic RNA Due to the R203K/G204R Variant in Nucleocapsid: Homologous Recombination has Potential to Change SARS-CoV-2 at Both Protein and RNA Level.","authors":"Shay Leary, Silvana Gaudieri, Matthew D Parker, Abha Chopra, Ian James, Suman Pakala, Eric Alves, Mina John, Benjamin B Lindsey, Alexander J Keeley, Sarah L Rowland-Jones, Maurice S Swanson, David A Ostrov, Jodi L Bubenik, Suman R Das, John Sidney, Alessandro Sette, Thushan I de Silva, Elizabeth Phillips, Simon Mallal","doi":"10.20411/pai.v6i2.460","DOIUrl":"10.20411/pai.v6i2.460","url":null,"abstract":"<p><strong>Background: </strong>Genetic variations across the SARS-CoV-2 genome may influence transmissibility of the virus and the host's anti-viral immune response, in turn affecting the frequency of variants over time. In this study, we examined the adjacent amino acid polymorphisms in the nucleocapsid (R203K/G204R) of SARS-CoV-2 that arose on the background of the spike D614G change and describe how strains harboring these changes became dominant circulating strains globally.</p><p><strong>Methods: </strong>Deep-sequencing data of SARS-CoV-2 from public databases and from clinical samples were analyzed to identify and map genetic variants and sub-genomic RNA transcripts across the genome. Results: Sequence analysis suggests that the 3 adjacent nucleotide changes that result in the K203/R204 variant have arisen by homologous recombination from the core sequence of the leader transcription-regulating sequence (TRS) rather than by stepwise mutation. The resulting sequence changes generate a novel sub-genomic RNA transcript for the C-terminal dimerization domain of nucleocapsid. Deep-sequencing data from 981 clinical samples confirmed the presence of the novel TRS-CS-dimerization domain RNA in individuals with the K203/R204 variant. Quantification of sub-genomic RNA indicates that viruses with the K203/R204 variant may also have increased expression of sub-genomic RNA from other open reading frames.</p><p><strong>Conclusions: </strong>The finding that homologous recombination from the TRS may have occurred since the introduction of SARS-CoV-2 in humans, resulting in both coding changes and novel sub-genomic RNA transcripts, suggests this as a mechanism for diversification and adaptation within its new host.</p>","PeriodicalId":36419,"journal":{"name":"Pathogens and Immunity","volume":"6 2","pages":"27-49"},"PeriodicalIF":0.0,"publicationDate":"2021-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8439434/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9343412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lack of Atorvastatin Effect on Monocyte Gene Expression and Inflammatory Markers in HIV-1-infected ART-suppressed Individuals at Risk of non-AIDS Comorbidities.","authors":"Anjana Yadav, Andrew V Kossenkov, Louise C Showe, Sarah J Ratcliffe, Grace H Choi, Luis J Montaner, Pablo Tebas, Pamela A Shaw, Ronald G Collman","doi":"10.20411/pai.v6i2.461","DOIUrl":"10.20411/pai.v6i2.461","url":null,"abstract":"<p><strong>Background: </strong>Many people living with HIV have persistent monocyte activation despite viral suppression by antiretroviral therapy (ART), which contributes to non-AIDS complications including neurocognitive and other disorders. Statins have immunomodulatory properties that might be beneficial by reducing monocyte activation.</p><p><strong>Methods: </strong>We previously characterized monocyte gene expression and inflammatory markers in 11 HIV-positive individuals on long-term ART (HIV/ART) at risk for non-AIDS complications because of low nadir CD4+ counts (median 129 cells/uL) and elevated hsCRP. Here, these individuals participated in a double-blind, randomized, placebo-controlled crossover study of 12 weeks of atorvastatin treatment. Monocyte surface markers were assessed by flow cytometry, plasma mediators by ELISA and Luminex, and monocyte gene expression by microarray analysis.</p><p><strong>Results: </strong>Among primary outcome measures, 12 weeks of atorvastatin treatment led to an unexpected increase in CCR2+ monocytes (<i>P</i>=0.04), but did not affect CD16+ or CD163+ monocytes, nor levels in plasma of CCL2/MCP-1 or sCD14. Among secondary outcomes, atorvastatin treatment was associated with decreased plasma hsCRP (<i>P</i>=0.035) and IL-2R (<i>P</i>=0.012). Treatment was also associated with increased total CD14+ monocytes (<i>P</i>=0.015), and increased plasma CXCL9 (<i>P</i>=0.003) and IL-12 (<i>P</i><0.001). Comparable results were seen in a subgroup that had inflammatory marker elevations at baseline. Atorvastatin treatment did not significantly alter monocyte gene expression or normalize aberrant baseline transcriptional patterns.</p><p><strong>Conclusions: </strong>In this study of aviremic HIV+ individuals at high risk of non-AIDS events, 12 weeks of atorvastatin did not normalize monocyte gene expression patterns nor lead to significant changes in monocyte surface markers or plasma mediators linked to non-AIDS comorbidities.</p>","PeriodicalId":36419,"journal":{"name":"Pathogens and Immunity","volume":" ","pages":"1-26"},"PeriodicalIF":0.0,"publicationDate":"2021-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382234/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39356480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Diagnosis of SARS-CoV-2: Assessing and Interpreting Nucleic Acid and Antigen Tests.","authors":"Peter A Zimmerman, Christopher L King, Mahmoud Ghannoum, Robert A Bonomo, Gary W Procop","doi":"10.20411/pai.v6i1.422","DOIUrl":"10.20411/pai.v6i1.422","url":null,"abstract":"<p><p>In this review, we summarize the current status of nucleic acid and antigen testing required for diagnosing SARS-CoV-2 infection and COVID-19 disease. Nucleic acid amplification (NAAT) and antigen-detection (Ag) tests occupy a critically important frontline of defense against SARS-CoV-2 in clinical and public health settings. In early stages of this outbreak, we observed that identifying the causative agent of a new illness of unknown origin was greatly accelerated by characterizing the nucleic acid signature of the novel coronavirus. Results from nucleic acid sequencing led to the development of highly sensitive RT-PCR testing for use in clinical settings and to informing best practices for patient care, and in public health settings to the development of strategies for protecting populations. As the current COVID-19 pandemic has evolved, we have seen how NAAT performance has been used to guide and optimize specimen collection, inform patient triage decisions, reveal unexpected clinical symptoms, clarify risks of transmission within patient care facilities, and guide appropriate treatment strategies. For public health settings during the earliest stages of the pandemic, NAATs served as the only tool available for studying the epidemiology of this new disease by identifying infected individuals, studying transmission patterns, modeling population impacts, and enabling disease control organizations and governments to make challenging disease mitigation recommendations to protect the expanding breadth of populations at risk. With time, the nucleic acid signature has provided the information necessary to understand SARS-CoV-2 protein expression for further development of antigen-based point-of-care (POC) diagnostic tests. The advent of massive parallel sequencing (ie, next generation sequencing) has afforded the characterization of this novel pathogen, informed the sequences best adapted for RT-PCR assays, guided vaccine production, and is currently used for tracking and monitoring SARS-CoV-2 variants.</p>","PeriodicalId":36419,"journal":{"name":"Pathogens and Immunity","volume":"6 1","pages":"135-156"},"PeriodicalIF":0.0,"publicationDate":"2021-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360705/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39323178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva.","authors":"Thomas J Ketas,&nbsp;Devidas Chaturbhuj,&nbsp;Victor M Cruz Portillo,&nbsp;Erik Francomano,&nbsp;Encouse Golden,&nbsp;Sharanya Chandrasekhar,&nbsp;Gargi Debnath,&nbsp;Randy Díaz-Tapia,&nbsp;Anila Yasmeen,&nbsp;Kyle D Kramer,&nbsp;Tarek Munawar,&nbsp;Wilhelm Leconet,&nbsp;Zhen Zhao,&nbsp;Philip J M Brouwer,&nbsp;Melissa M Cushing,&nbsp;Rogier W Sanders,&nbsp;Albert Cupo,&nbsp;Per Johan Klasse,&nbsp;Silvia C Formenti,&nbsp;John P Moore","doi":"10.20411/pai.v6i1.441","DOIUrl":"10.20411/pai.v6i1.441","url":null,"abstract":"<p><p>The approved Pfizer and Moderna mRNA vaccines are well known to induce serum antibody responses to the SARS-CoV-2 Spike (S)-protein. However, their abilities to elicit mucosal immune responses have not been reported. Saliva antibodies represent mucosal responses that may be relevant to how mRNA vaccines prevent oral and nasal SARS-CoV-2 transmission. Here, we describe the outcome of a cross-sectional study on a healthcare worker cohort (WELCOME-NYPH), in which we assessed whether IgM, IgG, and IgA antibodies to the S-protein and its receptor-binding domain (RBD) were present in serum and saliva samples. Anti-S-protein IgG was detected in 14/31 and 66/66 of saliva samples from uninfected participants after vaccine doses-1 and -2, respectively. IgA antibodies to the S-protein were present in 40/66 saliva samples after dose 2. Anti-S-protein IgG was present in every serum sample from recipients of 2 vaccine doses. Vaccine-induced antibodies against the RBD were also frequently present in saliva and sera. These findings may help our understanding of whether and how vaccines may impede SARS-CoV-2 transmission, including to oral cavity target cells.</p>","PeriodicalId":36419,"journal":{"name":"Pathogens and Immunity","volume":"6 1","pages":"116-134"},"PeriodicalIF":0.0,"publicationDate":"2021-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201795/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39238686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of 2 Ultraviolet-C Light Boxes for Decontamination of N95 Respirators.","authors":"Jennifer L Cadnum,&nbsp;Basya S Pearlmutter,&nbsp;Daniel F Li,&nbsp;Annette L Jencson,&nbsp;Jacob G Scott,&nbsp;Ian C Charnas,&nbsp;Curtis J Donskey","doi":"10.20411/pai.v6i1.432","DOIUrl":"https://doi.org/10.20411/pai.v6i1.432","url":null,"abstract":"<p><strong>Background: </strong>Ultraviolet-C (UV-C) light devices are effective in reducing contamination on N95 filtering facepiece respirators. However, limited information is available on whether UV-C devices meet the Food and Drug Administration's (FDA) microbiological requirements for Emergency Use Authorization (EUA) for respirator bioburden reduction.</p><p><strong>Methods: </strong>We tested the ability of 2 UV-C light boxes to achieve the 3-log₁₀ microorganism reductions required for EUA for reuse by single users. Whole 3M 1860 or Moldex 1513 respirators were inoculated on the exterior facepiece, interior facepiece, and internal fibers with bacteriophage MS2 and/or 4 strains of bacteria and treated with UV-C cycles of 1 or 20 minutes. Colorimetric indicators were used to assess penetration of UV-C through the respirators.</p><p><strong>Results: </strong>For 1 UV-C box, a 20-minute treatment achieved the required bioburden reduction for Moldex 1513 but not 3M 1860 respirators. For the second UV-C box, a 1-minute treatment achieved the required bioburden reduction in 4 bacterial strains for the Moldex 1513 respirator. Colorimetric indicators demonstrated penetration of UV-C through all layers of the Moldex 1513 respirator but not the 3M 1860 respirator.</p><p><strong>Conclusions: </strong>Our findings demonstrate that UV-C box technologies can achieve bioburden reductions required by the FDA for EUA for single users but highlight the potential for variable efficacy for different types of respirators.</p>","PeriodicalId":36419,"journal":{"name":"Pathogens and Immunity","volume":"6 1","pages":"104-115"},"PeriodicalIF":0.0,"publicationDate":"2021-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201793/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39238685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping Review.","authors":"Jessica M Jones, Aiman J Faruqi, James K Sullivan, Cassandra Calabrese, Leonard H Calabrese","doi":"10.20411/pai.v6i1.435","DOIUrl":"10.20411/pai.v6i1.435","url":null,"abstract":"<p><strong>Background: </strong>The role of humoral immunity has been well established in reducing infection risk and facilitating viral clearance in patients with COVID-19. However, the relationship between specific antibody responses and severity of COVID-19 is less well understood.</p><p><strong>Methods: </strong>To address this question and identify gaps in knowledge, we utilized the methodology of a scoping review to interrogate risk of infection and clinical outcomes of COVID-19 in patients with iatrogenic and inborn humoral immunodeficiency states based on existing literature.</p><p><strong>Results: </strong>Among patients with iatrogenic B-cell depletion, particularly with agents targeting CD20, our analysis found increased risk of severe COVID-19 and death across a range of underlying disease states. Among patients with humoral inborn errors of immunity with COVID-19, our synthesis found that patients with dysregulated humoral immunity, predominantly common variable immunodeficiency (CVID), may be more susceptible to severe COVID-19 than patients with humoral immunodeficiency states due to X-linked agammaglobulinemia and other miscellaneous forms of humoral immunodeficiency. There were insufficient data to appraise the risk of COVID-19 infection in both populations of patients.</p><p><strong>Conclusions: </strong>Our work identifies potentially significant predictors of COVID-19 severity in patients with humoral immunodeficiency states and highlights the need for larger studies to control for clinical and biologic confounders of disease severity.</p>","PeriodicalId":36419,"journal":{"name":"Pathogens and Immunity","volume":"6 1","pages":"76-103"},"PeriodicalIF":0.0,"publicationDate":"2021-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150936/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39033342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Life As Haiku","authors":"D. Douek","doi":"10.20411/PAI.V6I1.442","DOIUrl":"https://doi.org/10.20411/PAI.V6I1.442","url":null,"abstract":"Life is no haikuAnd I would tell you why notIf I had the timeTo","PeriodicalId":36419,"journal":{"name":"Pathogens and Immunity","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42950765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2-Priming Protease TMPRSS2.","authors":"Nurit P Azouz, Andrea M Klingler, Victoria Callahan, Ivan V Akhrymuk, Katarina Elez, Lluís Raich, Brandon M Henry, Justin L Benoit, Stefanie W Benoit, Frank Noé, Kylene Kehn-Hall, Marc E Rothenberg","doi":"10.20411/pai.v6i1.408","DOIUrl":"10.20411/pai.v6i1.408","url":null,"abstract":"<p><strong>Background: </strong>Host proteases have been suggested to be crucial for dissemination of MERS, SARS-CoV, and SARS-CoV-2 coronaviruses, but the relative contribution of membrane versus intracellular proteases remains controversial. Transmembrane serine protease 2 (TMPRSS2) is regarded as one of the main proteases implicated in the coronavirus S protein priming, an important step for binding of the S protein to the angiotensin-converting enzyme 2 (ACE2) receptor before cell entry.</p><p><strong>Methods: </strong>We developed a cell-based assay to identify TMPRSS2 inhibitors. Inhibitory activity was established in SARS-CoV-2 viral load systems.</p><p><strong>Results: </strong>We identified the human extracellular serine protease inhibitor (serpin) alpha 1 anti-trypsin (A1AT) as a novel TMPRSS2 inhibitor. Structural modeling revealed that A1AT docked to an extracellular domain of TMPRSS2 in a conformation that is suitable for catalysis, resembling similar serine protease inhibitor complexes. Inhibitory activity of A1AT was established in a SARS-CoV-2 viral load system. Notably, plasma A1AT levels were associated with COVID-19 disease severity.</p><p><strong>Conclusions: </strong>Our data support the key role of extracellular serine proteases in SARS CoV-2 infections and indicate that treatment with serpins, particularly the FDA-approved drug A1AT, may be effective in limiting SARS-CoV-2 dissemination by affecting the surface of the host cells.</p>","PeriodicalId":36419,"journal":{"name":"Pathogens and Immunity","volume":"6 1","pages":"55-74"},"PeriodicalIF":0.0,"publicationDate":"2021-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097828/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38896896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}